Sam Brusco, Associate Editor01.23.24
AngioDynamics has received U.S. Food and Drug Administration (FDA) clearance for its Auryon XL catheter, a 225 cm radial access catheter for use with the Auryon atherectomy system to treat peripheral artery disease (PAD).
Auryon XL is available in 0.9 mm and 1.5 mm diameters. It expands treatment access points in atherectomy procedures for PAD and may reduce major bleeding incidents, according to the company. It may also remove the need for use of femoral closure devices and allow treatment of bilateral disease in a single session.
The company began limited market release of Auryon XL in the U.S. this month, and expects to start full release in February.
“Since its launch in September 2020, the Auryon Atherectomy System, with its innovative solid-state laser technology, has fundamentally changed patient treatment for PAD and quickly become an essential tool for providers and patients,” said Kimberly Nelson, senior director of Auryon global marketing at AngioDynamics. “Our entry into the Radial-to-Peripheral (R2P) space with Auryon XL is an important part of our focus on advancing the quality of care delivery and it demonstrates our commitment to meeting the unmet needs of patients and atherectomy providers.”
Studies have shown that radial access is associated with much lower risk of major bleeding and access site complications when compared to femoral access.
"Radial access is more than an entry point; it's a transformative expressway to enhanced patient outcomes,” said Ankur Lodha, MD, interventional cardiologist at Cardiovascular Institute of the South located in Lafayette, La. “With an innovative design and its ease-of-use, the Auryon XL Catheter brings significant advancements to radial procedures as the first non-orbital atherectomy device—setting a new standard for laser atherectomy technology.”
Auryon XL is available in 0.9 mm and 1.5 mm diameters. It expands treatment access points in atherectomy procedures for PAD and may reduce major bleeding incidents, according to the company. It may also remove the need for use of femoral closure devices and allow treatment of bilateral disease in a single session.
The company began limited market release of Auryon XL in the U.S. this month, and expects to start full release in February.
“Since its launch in September 2020, the Auryon Atherectomy System, with its innovative solid-state laser technology, has fundamentally changed patient treatment for PAD and quickly become an essential tool for providers and patients,” said Kimberly Nelson, senior director of Auryon global marketing at AngioDynamics. “Our entry into the Radial-to-Peripheral (R2P) space with Auryon XL is an important part of our focus on advancing the quality of care delivery and it demonstrates our commitment to meeting the unmet needs of patients and atherectomy providers.”
Studies have shown that radial access is associated with much lower risk of major bleeding and access site complications when compared to femoral access.
"Radial access is more than an entry point; it's a transformative expressway to enhanced patient outcomes,” said Ankur Lodha, MD, interventional cardiologist at Cardiovascular Institute of the South located in Lafayette, La. “With an innovative design and its ease-of-use, the Auryon XL Catheter brings significant advancements to radial procedures as the first non-orbital atherectomy device—setting a new standard for laser atherectomy technology.”